Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:public_company
|
| gptkbp:CEO |
gptkb:Richard_Pops
|
| gptkbp:countryOfOperation |
gptkb:Ireland
|
| gptkbp:CUSIP |
G01767105
|
| gptkbp:focusesOn |
oncology
central nervous system disorders |
| gptkbp:foundedYear |
1987
|
| gptkbp:hasCompany |
gptkb:Alkermes_plc
|
| gptkbp:headquartersLocation |
gptkb:Dublin,_Ireland
|
| https://www.w3.org/2000/01/rdf-schema#label |
NASDAQ: ALKS
|
| gptkbp:industry |
biopharmaceuticals
|
| gptkbp:ISIN |
IE00B56GVS15
|
| gptkbp:listedSince |
1991
|
| gptkbp:marketCap |
multi-billion USD (as of 2024)
|
| gptkbp:notableProduct |
gptkb:Aristada
gptkb:Lybalvi gptkb:Vivitrol |
| gptkbp:numberOfEmployees |
~2,200
|
| gptkbp:researchFacilityLocation |
gptkb:Waltham,_Massachusetts,_USA
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:ALKS
|
| gptkbp:tradedOn |
gptkb:NASDAQ:_ALKS
|
| gptkbp:website |
https://www.alkermes.com/
|
| gptkbp:bfsParent |
gptkb:Alkermes
|
| gptkbp:bfsLayer |
7
|